Figure 6.

PPARγ agonist treatment increases serum adiponectin levels but cannot protect renal function. (A) Serum adiponectin is increased with PPARγ agonist treatment (COOH), but not to the levels of POD-Tg mice. (B) Podocyte numbers were not significantly restored at 0.5 µg/g in POD-KO mice with COOH, but recovery of WT1+ podocytes per glomerular area was increased by PPARγ agonist treatment in POD mice. (C) PPARγ agonist–treated POD-KO and POD mice demonstrate loss of ClCr (µl/min) similar to that of untreated mice at 0.5 µg/g. (D) Albuminuria is increased 10 times over mice not treated with PPARγ agonist at day 2 and, although it is reduced by day 28, is not improved by PPARγ agonist treatment. (E) PPARγ agonist treatment does not protect POD-ATTAC mice from interstitial fibrosis or aid in recovery through day 60. Bar, 10× = 200 µm; 40× = 50 µm. (F) Quantified interstitial fibrosis of PPARγ agonist–treated mice demonstrated equivalent, or worse, fibrosis compared with untreated POD mice at days 28 and 60. *0.05>P>0.01, **0.01>P>0.001, ***P<0.001 from the baseline (day 0 or POD d0 baseline versus adiponectin mouse models or COOH treatment); ^#0.05>P>0.01, ^###P<0.001 from the peak of time course data